The influence of probucol on hs-CRP and Hcy of patients with non-ST-segment elevation acute coronary syndrome

VernacularTitle:普罗布考对非ST段抬高型急性冠脉综合征患者血浆超敏C反应蛋白和同型半胱氨酸的影响
Author: Jinjing DING
Publication Type:Journal Article
Keywords: Myocardial ischemia; C-reactive protein; Cysteine; Probucol
From: Chinese Journal of Primary Medicine and Pharmacy 2013;20(14):2159-2161
CountryChina
Language:Chinese
Abstract: Objective To explore the influence of probucol on high-sensitive C-reactive protein (hs-CRP)and homocysteine(Hcy) of patients with non-ST-segment elevation acute coronary syndrome.Methods 82 patients with non-ST-segment elevation acute coronary syndrome were randomly divided into two groups,the control group (40 cases) and the treatment group (42 cases).The patients in the control group were treated through the conventional treatment,while the patients in the treatment group were treated by probucol on the basis of conventional therapy.They were all treated for three months.Serum levels of hs-CRP and Hcy were detected before and after treatment.Results Serum levels of hs-CRP and Hcy were all decreased after treatment in both two groups.The hs-CRP and Hcy in the treatment group were significantly improved than those of the control group [(0.82 ± 0.43) mg/L vs (1.05 ± 0.52) mg/L,(10.08 ± 7.18) μnol/L vs (15.73 ± 9.16) μmol/L,t =2.1871,3.1168,all P ＜ 0.05].Conclusion Probucol can significantly decrease the serum levels of hs-CRP and Hcy in patients with non-ST-segment elevation acute coronary syndrome.